Neurobiological Technologies NTII · USD

Market value

$2,695

Last close × shares

Volume

1.1k

Shares, 30 Oct 2026

Its shares trade under the ticker NTII. It has been listed since 16 February 1994. In the fiscal year to 30 June 2010, it reported revenue of $6.0m and net income of $4.9m. At that date it held total assets of $2.6m and shareholders' equity of $1.5m.

Neurobiological Technologies, Inc. manufactures biological products. The company is headquartered in San Ramon, California. On October 27, 2009, the Company’s stockholders approved the dissolution of the Company pursuant to a plan of complete liquidation and dissolution earlier approved by its board of directors on August 27, 2009 (the Plan of Dissolution). As a Company in dissolution, NTI was not allowed to carry on any business except for the purpose of winding down the business and affairs of the Company. On December 17, 2009, the Company filed a certificate of dissolution with the Secretary of State of the State of Delaware (the Certificate of Dissolution). As of June 30, 2010, NTI retains an interest in an investigational drug called XERECEPT, which is a synthetic preparation of Corticotropin-Releasing Factor, a natural human peptide. XERECEPT is being developed by Celtic Pharma as a treatment for swelling around brain tumors and other cancer indications.

Figures and description from our data supplier, not checked against the company's own report.

More about Neurobiological Technologies →

We have not reported on Neurobiological Technologies yet.

Leaves out fees, taxes and financing.

Chart

TradingView

Close and company data

Our data supplier

News

Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.